NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free ACAD Stock Alerts $15.40 +0.08 (+0.52%) (As of 03:56 PM ET) Add Compare Share Share Today's Range$15.18▼$15.4150-Day Range$14.62▼$18.4952-Week Range$14.60▼$33.99Volume631,726 shsAverage Volume1.77 million shsMarket Capitalization$2.54 billionP/E RatioN/ADividend YieldN/APrice Target$28.94 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ACADIA Pharmaceuticals alerts: Email Address ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside88.3% Upside$28.94 Price TargetShort InterestBearish7.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 12 Articles This WeekInsider TradingSelling Shares$1.44 M Sold Last QuarterProj. Earnings Growth79.31%From $0.58 to $1.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.05 out of 5 starsMedical Sector165th out of 904 stocksPharmaceutical Preparations Industry68th out of 428 stocks 4.4 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.25% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.8 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for ACADIA Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest21 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows12 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,441,922.00 in company stock.Percentage Held by Insiders28.30% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 79.31% in the coming year, from $0.58 to $1.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -1,535.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -1,535.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesJune 5 at 11:46 PM | seekingalpha.comAcadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS TreatmentsJune 4 at 1:54 AM | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Earn Q1 2026 Earnings of $0.22 Per ShareMay 31, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for ACADIA Pharmaceuticals Inc. Issued By Zacks Research (NASDAQ:ACAD)May 27, 2024 | finanznachrichten.deNeuren Pharmaceuticals Ltd: Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndromeMay 23, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)May 17, 2024 | businesswire.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 17, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS) and Elicio Therapeutics (ELTX)May 15, 2024 | stocknews.com3 Pharma Stocks to Buy for Potential Financial FortunesMay 15, 2024 | businesswire.comAcadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett SyndromeMay 11, 2024 | markets.businessinsider.comNeutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration ForecastsMay 11, 2024 | finance.yahoo.comResults: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 10, 2024 | markets.businessinsider.comBuy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial StabilityMay 10, 2024 | finance.yahoo.comACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | markets.businessinsider.comPositive Buy Rating for ACADIA Pharmaceuticals Amid Solid Market Presence and Underestimated Long-Term OpportunitiesMay 9, 2024 | markets.businessinsider.comMaintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue’s Long-Term Growth ProspectsMay 9, 2024 | msn.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | businesswire.comAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 9, 2024 | markets.businessinsider.comACADIA Pharmaceuticals: Strong Sales and Promising Pipeline Justify Buy RatingMay 9, 2024 | finance.yahoo.comACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...May 8, 2024 | investorplace.comACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | seekingalpha.comACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | markets.businessinsider.comACADIA Pharmaceuticals is about to announce its earnings — here's what Wall Street expectsMay 4, 2024 | finance.yahoo.comInsider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)May 2, 2024 | stocknews.comBuy Alert: 3 Pharma Stocks Under $20 to Invest in NowMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Sarepta Therapeutics (SRPT) and Acadia Healthcare (ACHC)See More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/06/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$28.94 High Stock Price Target$42.00 Low Stock Price Target$19.00 Potential Upside/Downside+88.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio26.41 P/E GrowthN/ANet Income$-61,290,000.00 Net Margins-0.21% Pretax Margin1.83% Return on Equity-0.41% Return on Assets-0.24% Debt Debt-to-Equity RatioN/A Current Ratio2.04 Quick Ratio1.86 Sales & Book Value Annual Sales$726.44 million Price / Sales3.48 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book5.83Miscellaneous Outstanding Shares165,220,000Free Float118,463,000Market Cap$2.53 billion OptionableOptionable Beta0.40 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 63)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 55)Executive VP, COO & Head of Commercial Comp: $724.31kMr. James K. Kihara (Age 43)VP, Chief Accounting Officer & Corporate Controller Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Executive VP & Head of Research and Development Mr. Benir RuanoSenior Vice President of Technical Development & OperationsMr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsMs. Jennifer J. Rhodes J.D. (Age 54)Executive VP, Chief Legal Officer & Secretary Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyMs. Holly ValdiviezSenior VP & Head of SalesMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCMirati TherapeuticsNASDAQ:MRTXCatalentNYSE:CTLTElanco Animal HealthNYSE:ELANRoivant SciencesNASDAQ:ROIVView All CompetitorsInsiders & InstitutionsDekaBank Deutsche GirozentraleBought 2,731 shares on 6/4/2024Ownership: 0.059%Verity Asset Management Inc.Bought 11,668 shares on 5/28/2024Ownership: 0.007%Virtu Financial LLCBought 15,412 shares on 5/20/2024Ownership: 0.009%Walleye Trading LLCBought 1,300 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 5,917 shares on 5/16/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price target for 2024? 16 Wall Street analysts have issued 1-year price objectives for ACADIA Pharmaceuticals' shares. Their ACAD share price targets range from $19.00 to $42.00. On average, they expect the company's share price to reach $28.94 in the next year. This suggests a possible upside of 88.3% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2024? ACADIA Pharmaceuticals' stock was trading at $31.31 at the start of the year. Since then, ACAD stock has decreased by 50.9% and is now trading at $15.37. View the best growth stocks for 2024 here. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.06. The biopharmaceutical company had revenue of $205.83 million for the quarter, compared to analyst estimates of $208.31 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 0.41% and a negative net margin of 0.21%. ACADIA Pharmaceuticals's quarterly revenue was up 73.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.27) earnings per share. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO), Invesco Biotechnology & Genome ETF (PBE) and Virtus LifeSci Biotech Products ETF (BBP).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $966.6 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.05%), Price T Rowe Associates Inc. MD (2.42%), Jupiter Asset Management Ltd. (0.97%), Rice Hall James & Associates LLC (0.40%), Nordea Investment Management AB (0.20%) and M&G Plc (0.19%). Insiders that own company stock include Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACAD) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.